GMDA News and Press, Gamida Cell Ltd. From 05/13/20

SIFCO (NYSEMKT: SIF ) +61%  on Q2 results . More news on: SIFCO Industries, Inc., United Natural Foods, Inc., Cyclacel Pharmaceuticals, Inc., Stocks on the move, , Read more ...

Gainers: CymaBay Therapeutics (NASDAQ: CBAY ) +134% . More news on: CymaBay Therapeutics, Inc., Novavax, Inc., Babcock & Wilcox Enterprises, Inc., Stocks on the move, , Read more ...

Gamida Cell (NASDAQ: GMDA ) is up  86%  premarket after announcing positive topline results from its Phase 3 study evaluating the safety and efficacy of omidubicel, an investigational advanced cell therapy as a potential life-saving treatment option for patients in need of b...

— Study met primary endpoint of time to neutrophil engraftment — — Omidubicel represents potential transformative treatment option for patients in need of a bone marrow transplant — — Company anticipates initiating BLA submission in fourth quart...

Gamida Cell Ltd. (GMDA) Q4 2019 Results Earnings Conference Call February 25, 2020, 08:30 AM ET Company Participants Jaren Madden - Vice President, Investor Relations and Corporate Communications Julian Adams - CEO Ronit Simantov - Chief Medical Officer Shai Lankry - CFO Thom...

Gamida Cell (NASDAQ: GMDA ): FY GAAP EPS of -$1.69 misses by $0.62 . More news on: Gamida Cell Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

– Completed patient enrollment in Phase 3 clinical study of omidubicel; Topline data expected in the second quarter of 2020 – – Company to host conference call at 8:30 a.m. ET today – Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company com...

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, February 25, 2020, at 8:30 a.m. ET to review its full year 2019 fi...

– Topline data from Phase 3 study of omidubicel expected in first half of 2020 – – GDA-201 program progressing with additional data expected in first half of 2020 – – Jas Uppal, Ph.D., appointed as chief regulatory and quality officer – ...

– Topline data expected in first half of 2020 – Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, announced that in December the company completed patient enrollment in its Phase 3 ...